Biomerica Reports First Quarter Fiscal 2027 Financial Results
Biomerica reported Q1 fiscal 2027 net sales of approximately $1.3 million, down from $1.4 million a year ago, with a net loss of $1.2 million ($0.37 per share) versus prior-year breakeven that included ~$1.1 million of ERC income. Commercial momentum is building for inFoods IBS: Medicare-related test orders rose 120% month-over-month to 22 in September, and 100% of initial valid Medicare claims have been paid at the full $300 CMS rate. Cash more than doubled to $2.7 million following an August private placement at $1.60 per share that raised $2.23 million, with participation from B. Riley Principal Capital and all board members.
Key figures
- Revenue
- 1300000
- Cash
- 2700000
- Opex
- 1300000
- Net loss
- 1200000
- Otc sales
- 291000
- Gross margin
- 8%
- Gross profit
- 103000
- Operating loss
- 1200000
- Opex change yoy
- -14%
- Working capital
- 2600000
- Cms payment rate
- 300
- Otc sales growth
- 81%
- Operating cash use
- 802000
- Prior year gross margin
- 31%
- Private placement price
- 1.6
- Private placement shares
- 1390000
- Medicare order growth mom
- 120%
- Medicare ordering locations
- 32
- Msa target development fees
- 1750000
- Private placement gross proceeds
- 2230000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.